المؤلفون: Li Zhang, Xin Mei, Zhigang Hu, Bo Yu, Chaoyang Zhang, Yong Li, Kaitai Liu, Xuejun Ma, Jinli Ma, Xingxing Chen, Jin Meng, Wei Shi, Xiaofang Wang, Miao Mo, Zhimin Shao, Zhen Zhang, Xiaoli Yu, Xiaomao Guo, Zhaozhi Yang

المصدر: BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)

مصطلحات موضوعية: Breast cancer, Supraclavicular nodal irradiation, Target volume, Survival outcome, Toxicity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background Supraclavicular nodal (SCL) irradiation is commonly used for patients with high-risk breast cancer after breast surgery. The Radiation Therapy Oncology Group (RTOG) and European Society for Radiotherapy and Oncology (ESTRO) breast contouring atlases delineate the medial part of the SCL region, while excluding the posterolateral part. However, recent studies have found that a substantial proportion of SCL failures are located in the posterolateral SCL region, outside of the RTOG/ESTRO-defined SCL target volumes. Consequently, many radiation oncologists advocate for enlarging the SCL irradiation target volume to include both the medial and posterolateral SCL regions. Nevertheless, it remains uncertain whether adding the posterolateral SCL irradiation improves survival outcomes for high-risk breast cancer patients. Methods The SUCLANODE trial is an open-label, multicenter, randomized, phase 3 trial comparing the efficacy and adverse events of medial SCL irradiation (M-SCLI group) and medial plus posterolateral SCL irradiation (entire SCL irradiation, E-SCLI group) in high-risk breast cancer patients who underwent breast conserving-surgery or mastectomy. Patients with pathological N2-3b disease following initial surgery, or clinical stage III or pathological N1-3b if receiving neoadjuvant systemic therapy, are eligible and randomly assigned (1:1) to M-SCLI group and E-SCLI group. Stratification is by chemotherapy sequence (neoadjuvant vs. adjuvant), T stage (T3-4 vs. T1-2), N stage (N1-2 vs. N3), and ER status (positive vs. negative). Other radiation volumes are identical in the two arms, including breast/chest wall, undissected axillary lymph node, and internal mammary node. Advanced intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), or tomotherapy techniques are recommended. Both hypofractionated and conventional fractionation schedules are permitted. The primary end point is invasive disease-free survival, and secondary end points included overall survival, SCL recurrence, local-regional recurrence, distance recurrence, safety outcome, and patient-reported outcomes. The target sample size is 1650 participants. Discussion The results of the SUCLANODE trial will provide high-level evidence regarding whether adding posterolateral SCL irradiation to medial SCL target volume provides survival benefit in patients with high-risk breast cancer. Trial registration ClinicalTrials.gov Identifier: NCT05059379. Registered 28 September 2021, https://www.clinicaltrials.gov/ct2/show/NCT05059379Test .

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/5ae6101bd1f04e779cd16f7e8250dde9Test

المؤلفون: Zhen Zhang, Wenhui Gao, Xiaoning Tan, Tianhao Deng, Wanshuang Zhou, Huiying Jian, Puhua Zeng

المصدر: BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)

مصطلحات موضوعية: Hepatocellular carcinoma, Circadian clock, lncRNA, Immune infiltration, Risk model, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Circadian clock genes are significant in the occurrence and development of HCC and long-non coding RNAs (lncRNAs) are closely related to HCC progression. In this study, we aimed to establish a prognostic risk model for HCC. Circadian clock-related lncRNAs expressed in HCC were extracted from The Cancer Genome Atlas. A nomogram was established to predict individual survival rate. Biological processes enriched for risk model transcripts were investigated by Gene Set Enrichment Analysis. Further, we evaluated the relationship between risk score and immune-checkpoint inhibitor-related gene expression level. The Genomics of Drug Sensitivity in Cancer (GDSC) database was used to assess the sensitivity of tumors in high- and low-risk score groups to different drugs. A total of 11 circadian clock-related lncRNAs were included in multi-Cox proportional hazards model analysis to establish a risk model. Univariate and multivariate Cox regression analysis showed that the risk model was an independent risk factor in HCC. The risk model was a significantly associated with the immune signature. Further GDSC analysis indicated that patients in each risk score group may be sensitive to different anti-cancer drugs. QRT-PCR analysis results showed that C012073.1, PRRT3-AS1, TMCC1-AS1, LINC01138, MKLN1-AS, KDM4A-AS1, AL031985.3, POLH-AS1, LINC01224, and AC099850.3 were more highly expressed in Huh-7 and HepG2, compared to LO2, while AC008549.1 were lower expressed. Our work established a prognostic model for HCC. Risk score analysis indicated that the model is significantly associated with modulation tumor immunity and could be used to guide more effective therapeutic strategies in the future.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/98772bd8cb254311a0fa3f899074020aTest

المؤلفون: Menglong Zhou, Wang Yang, Yan Xuan, Wei Zou, Yaqi Wang, Zhiyuan Zhang, Jing Zhang, Miao Mo, Changming Zhou, Yuan Liu, Wenming Zhang, Zhaozhen Zhang, Yiping He, Weiwei Weng, Cong Tan, Lei Wang, Dan Huang, Weiqi Sheng, Huanhuan Li, Hui Zhu, Yan Wang, Lijun Shen, Hui Zhang, Juefeng Wan, Guichao Li, Hua Huang, Yanong Wang, Zhen Zhang, Xiaowen Liu, Fan Xia

المصدر: BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)

مصطلحات موضوعية: Locally advanced gastric cancer, Gastroesophageal junction adenocarcinoma, Preoperative chemoradiation, Immunotherapy, Gastrectomy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background Perioperative chemotherapy (ChT) and preoperative chemoradiation (CRT) are both the standard treatments for locally advanced gastric cancer (LAGC). CRT can achieve a higher pathological complete regression (pCR) rate, but whether this higher pCR rate can be transformed into a long-term survival benefit remains inconclusive. Therefore, relevant studies are in progress. On the other hand, immunotherapy has been established for the first-line treatment of advanced gastric cancer (AGC) and has been widely explored in the perioperative setting. The combination of chemotherapy/radiotherapy and immunotherapy may have a synergistic effect, which will lead to a better antitumor effect. The preliminary reports of ongoing studies show promising results, including a further improved pCR rate. However, the preferred treatment combination for LAGC is still not established. To solve this problem, we are carrying out this randomized phase II trial, which aims to evaluate the efficacy and safety of perioperative chemotherapy plus the use of PD-1 antibody with or without preoperative chemoradiation for LAGC. Methods Eligible patients with LAGC or gastroesophageal junction (GEJ) adenocarcinoma were randomized to receive perioperative ChT, PD-1 antibody, surgery with (Arm A) or without preoperative CRT (Arm B), and PD-1 antibody maintenance until one year after surgery. The primary endpoint of this study is that the pCR rate of Arm A will be significantly higher than that of Arm B. The secondary endpoints include the pathological partial regression (pPR) rate, R0 resection rate, objective response rate (ORR), event-free survival (EFS), overall survival (OS), safety and surgical complications. Moreover, several explorative endpoints will be evaluated to find and validate the predictive biomarkers of immunotherapy. Discussion The results of the NeoRacing study will provide important information concerning the application of PD-1 antibody in LAGC patients during the perioperative setting. Meanwhile, the two treatment protocols will be compared in terms of efficacy and safety. Trial registration ClinicalTrials.gov , NCT05161572 . Registered 17 December 2021 - Retrospectively registered.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/5748f5af758b433e97f86a900f80c0edTest

المؤلفون: Yaqi Wang, Lijun Shen, Juefeng Wan, Hui Zhang, Ruiyan Wu, Jingwen Wang, Yan Wang, Ye Xu, Sanjun Cai, Zhen Zhang, Fan Xia

المصدر: BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)

مصطلحات موضوعية: Locally advanced rectal cancer, Immunotherapy, Short-course radiotherapy, Total neoadjuvant therapy, Complete response, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background For patients with locally advanced (T3-4/N +) rectal cancer (LARC), the standard treatment is neoadjuvant chemoradiotherapy combined with total mesorectal resection, which greatly decreases local recurrence but does not improve overall survival. For patients who achieve a complete clinical response (cCR) after nCRT, a “Watch & Wait” (W&W) approach can be received to improve quality of life. Currently, total neoadjuvant therapy (TNT) has been demonstrated to increase the complete response rate and achieve early control of distant metastasis. Recent studies have shown promising synergistic effects of the combination of immunotherapy (PD-1/PD-L1 antibodies) and radiotherapy. Thus, for LARC patients, the combination of immunotherapy and TNT is likely to further improve the rate of complete response and prognosis. The disparities between induction therapy and consolidation therapy need to be investigated. Methods TORCH is a randomized, prospective, multicentre, double-arm, phase II trial of short-course radiotherapy (SCRT) combined with chemotherapy and immunotherapy in LARC. 130 LARC patients will be treated with the TNT approach and assigned to the consolidation arm and induction arm. The consolidation arm will receive SCRT, followed by 6 cycles of capecitabine plus oxaliplatin (CAPOX) and Toripalimab. The induction arm will first receive 2 cycles of CAPOX and Toripalimab, then receive SCRT, followed by 4 cycles of CAPOX and Toripalimab. Both groups will receive curative surgery or the W&W strategy. The primary endpoint is the complete response rate (rate of pCR plus cCR). The secondary endpoints include the grade 3–4 acute adverse effects rate, 3-year disease-free survival (DFS) rate, 3-year local recurrence-free survival (LRFS) rate, 3-year OS rate, rate of surgical complications and quality of life (QoL) scores. The “pick the winner” method is used to investigate the better treatment regimen. The trial was opened on 13th April 2021, and the first patient was recruited on 6th May 2021. Discussion TORCH will investigate whether SCRT combined with chemotherapy and Toripalimab can achieve better complete response rates, good tolerance and prognosis in LARC patients. This is the first clinical trial to compare the efficacy of induced immunotherapy and consolidative immunotherapy based on the TNT strategy. Trial registration Trial Registration Number and Date of Registration: ClinicalTrials.gov NCT04518280 , August 15, 2020.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/df43c36e252048eaac3804d48a056962Test

المؤلفون: Yan Qi, Shuang-Shuang Dong, Yong-Lai He, Zi-Han Liu, Ya-Lan Huang, Ning Wang, Zhen Zhang, Zhong Li, Mei Er Tu He Ta Mi Shi, Xiao Feng, Qing Yao, Hong Zou, Jian-Ming Hu, Li-Juan Pang, Feng Li

المصدر: BMC Cancer, Vol 22, Iss 1, Pp 1-15 (2022)

مصطلحات موضوعية: SYT-SSX1, Cancer stem cell, Synovial sarcoma, TGF-β1/Smad, Signaling pathway, Epithelial–mesenchymal transition, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background Synovial sarcoma (SS) is a type of soft tissue sarcoma (STS) of undetermined tissue origin, which is characterized by the recurrent pathognomonic chromosomal translocation t (X;18)(p11.2; q11.2). Studies have shown that SS is a malignant tumor originating from cancer stem cells or pluripotent mesenchymal stem cells and may be related to fusion genes. In addition, some studies have indicated that the induction of epithelial–mesenchymal transition (EMT) via the TGF-β1/Smad signaling pathway leads to SS metastasis. Methods We analyzed the effects of SYT-SSX1 on the stemness of SS cells via TGF-β1/Smad signaling in vitro. The SYT-SSX1 fusion gene high expression cell was constructed by lentiviral stable transfer technology. SYT-SSX1 and SW982 cells were cultured and tested for sphere-forming ability. The transwell migration assay and flow cytometry were used to assess the migration ability of the sphere cells as well as the expression of CSC-related markers. We treated SYT-SSX1 cells with rhTGF-β1 (a recombinant agent of the TGF-β1 signaling pathway) and SB431542 and observed morphological changes. A CCK-8 experiment and a western blot (WB) experiment were conducted to detect the expression of TGF-β1 signaling pathway- and EMT-related proteins after treatment. The SYT-SSX1 cells were then cultured and their ability to form spheres was tested. Flow cytometry, WB, and quantitative real-time polymerase chain reaction (qRT-PCR) were used to detect the expression of CSC surface markers on SYT-SSX1 sphere cells. Results It was found that SYT-SSX1 has stronger sphere-forming ability, migration ability, and higher expression of CSC-related molecules than SW982 cells. Through treating SYT-SSX1 and SW982 cells with rhTGF-β1 and SB431542, we found that TGF-β1 enhanced the proliferation of cells, induced EMT, and that TGF-β1 enhanced the characteristics of tumor stem cells. Conclusions Our results suggest that SYT-SSX1 enhances invasiveness and maintains stemness in SS cells via TGF-β1/Smad signaling. These findings reveal an effective way to potentially improve the prognosis of patients with SS by eliminating the characteristics of cancer stem cells (CSCs) during treatment.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/1e818bd940684acdb13113ec843c8f79Test

المؤلفون: Xiang Jin, Yinghui Guan, Zhen Zhang, Hongyue Wang

المصدر: BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)

مصطلحات موضوعية: Non-small cell lung cancer, Differentially expressed genes, miRNA, Regulatory network, Microarray data analysis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background The aim of this study was to gain further investigation of non-small cell lung cancer (NSCLC) tumorigenesis and identify biomarkers for clinical management of patients through comprehensive bioinformatics analysis. Methods miRNA and mRNA microarray datasets were downloaded from GEO (Gene Expression Omnibus) database under the accession number GSE102286 and GSE101929, respectively. Genes and miRNAs with differential expression were identified in NSCLC samples compared with controls, respectively. The interaction between differentially expressed genes (DEGs) and differentially expressed miRNAs (DEmiRs) was predicted, followed by functional enrichment analysis, and construction of miRNA-gene regulatory network, protein-protein interaction (PPI) network, and competing endogenous RNA (ceRNA) network. Through comprehensive bioinformatics analysis, we anticipate to find novel therapeutic targets and biomarkers for NSCLC. Results A total of 123 DEmiRs (5 up- and 118 down-regulated miRNAs) and 924 DEGs (309 up- and 615 down-regulated genes) were identified. These genes and miRNAs were significantly involved in different pathways including adherens junction, relaxin signaling pathway, and axon guidance. Furthermore, hsa-miR-9-5p, has-miR-196a-5p and hsa-miR-31-5p, as well as hsa-miR-1, hsa-miR-218-5p and hsa-miR-135a-5p were shown to have higher degree in the miRNA-gene regulatory network and ceRNA network, respectively. Furthermore, BIRC5 and FGF2, as well as RTKN2 and SLIT3 were hubs in the PPI network and ceRNA network, respectively. Conclusion Several pathways (adherens junction, relaxin signaling pathway, and axon guidance) miRNAs (hsa-miR-9-5p, has-miR-196a-5p, hsa-miR-31-5p, hsa-miR-1, hsa-miR-218-5p and hsa-miR-135a-5p) and genes (BIRC5, FGF2, RTKN2 and SLIT3) may play important roles in the pathogenesis of NSCLC.

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12885-020-06829-xTest; https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/18a59b85eec44c33a473c826afa09421Test

المؤلفون: Qingguo Li, Dakui Luo, Ji Zhu, Lifeng Yang, Qi Liu, Yanlei Ma, Lei Liang, Sanjun Cai, Zhen Zhang, Xinxiang Li, ACRNaCT study group

المصدر: BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)

مصطلحات موضوعية: Neoadjuvant chemoradiotherapy, Adjuvant chemotherapy, Locally advanced rectal cancer, Yield pathological stage, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background The CAO/ARO/AIO-94 demonstrated that neoadjuvant chemoradiotherapy (CRT) could decrease the rate of local recurrence rather than distal metastases in advanced rectal cancer. Adjuvant chemotherapy (ACT) can eliminate micrometastasis, and render a better prognosis to rectal cancer. However, adoption of ACT mainly depends on the evidence from colon cancer. Neoadjuvant CRT can lead to tumor shrinkage in a number of patients with advanced rectal cancer. The administration of adjuvant therapy depending on pretreatment clinical stage or postoperative yield pathological (yp) stage remains controversial. At present, the clinical guidelines recommend ACT for patients with stage II/III (ypT3–4 N0 or ypTanyN1–2) rectal cancer following neoadjuvant CRT and surgery. However, the yp stage may influence the guidance of ACT. Methods According to the postoperative pathological stage, the present study was divided into two parts with different study design procedures. Patients will undergo different therapeutic strategies after collecting data related to postoperative pathological stage. For patients with pathologic complete response or yp stage I, the study was designed as a non-inferiority trial to compare the patients’ long-term outcomes in observational group and those in treatment group with 5-fluorouracil. For patients at yp stage II or III, the study was designed as a superiority trial to compare the oncological effect of oxaliplatin combined with 5-fluorouracil, in addition to 5-fluorouracil alone in ACT. The primary endpoint is 3-year disease-free survival (DFS). Secondary endpoints are 3-year, 5-year overall survival, 5-year DFS, and the rate of local recurrence and adverse events resulted from chemotherapy and the patients’ quality of life postoperatively. Discussion The ACRNaCT trial aims to investigate whether observation is not inferior than 5-fluorouracil for pathologic complete response or yp stage I, and indicate whether combined chemotherapy contains superior outcomes than 5-fluorouracil alone for yp stage II or III in patients receiving neoadjuvant CRT and surgery for locally advanced rectal cancer (LARC). This trial is expected to provide individualized adjuvant treatment strategies for LARC patients following neoadjuvant CRT and surgery. Trial registration The trial has been registered in ClinicalTrials.gov on January 30, 2018 (Registration No. NCT03415763), and also, that was registered in Chinese Clinical Trial Registry on November 12, 2018 (Registration No. ChiCTR1800019445).

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12885-019-6289-6Test; https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/085a67d726f544bead668ef33ae481eeTest

المؤلفون: Xiaowen Liu, Jiejie Jin, Hong Cai, Hua Huang, Guangfa Zhao, Ye Zhou, Jianghong Wu, Chunyan Du, Ziwen Long, Yantian Fang, Mingze Ma, Guichao Li, Menglong Zhou, Jiliang Yin, Xiaodong Zhu, Ji zhu, Weiqi Sheng, Dan Huang, Hui Zhu, Zhaozhen Zhang, Qi Lu, Li Xie, Zhen Zhang, Yanong Wang

المصدر: BMC Cancer, Vol 19, Iss 1, Pp 1-6 (2019)

مصطلحات موضوعية: Gastric cancer, Esophagogastric junction adenocarcinoma, Preoperative chemotherapy, Preoperative Chemoradiation, Gastrectomy, Adjuvant chemotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background The prognosis of patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma is still dismal. There are no standard treatment strategies for these patients. Multidisciplinary team (MDT) approach is a good choice for making a high-quality decision. Generally, MDT will recommend these patients to receive preoperative chemotherapy or preoperative chemoradiation based on all kinds of treatment guidelines. However, the preferred preoperative treatment is still not established. In order to solve this problem, we carry out this randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma. Methods Eligible patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma are randomized to receive preoperative chemoradiation or preoperative chemotherapy, followed by surgery and postoperative chemotherapy. In the preoperative chemoradiation arm (Pre-CRT), patients receive two cycles of S-1 and oxaliplatin (SOX), chemoradiation, then followed by surgery and three more cycles of SOX chemotherapy. In the preoperative chemotherapy arm (Pre-CT), patients receive three cycles of SOX, following surgery three more cycles of SOX are given. The primary endpoint of this trial is to verify that preoperative chemoradiation could significantly improve the 3-year disease free survival (DFS) of patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma compared to preoperative chemotherapy. Discussion The results from this trial will provide important information about whether preoperative chemoradiation could improve survival compared to preoperative chemotherapy among patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma. Trial registration ClinicalTrials.gov Identifier: NCT03013010. First posted January 6, 2017.

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12885-019-5728-8Test; https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/e38ab3b0ad6b4ae39ae34f53b6cb75bcTest

المؤلفون: Weiqi Sheng, Yanong Wang, Hua Huang, Dan Huang, Guangfa Zhao, Qi Lu, Hong Cai, Menglong Zhou, Zhaozhen Zhang, Zhen Zhang, Jianghong Wu, Jiejie Jin, Chunyan Du, Li Xie, Xiao-Dong Zhu, Mingze Ma, Ziwen Long, Guichao Li, Ye Zhou, Xiaowen Liu, Yantian Fang, Jiliang Yin, Hui Zhu, Ji Zhu

المصدر: BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-6 (2019)

مصطلحات موضوعية: Male, 0301 basic medicine, Cancer Research, Esophageal Neoplasms, medicine.medical_treatment, Study Protocol, 0302 clinical medicine, Surgical oncology, Clinical endpoint, Prospective Studies, Aged, 80 and over, Standard treatment, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Neoadjuvant Therapy, Oxaliplatin, Drug Combinations, Oncology, Preoperative Chemoradiation, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Adenocarcinoma, Female, Esophagogastric Junction, Radiology, medicine.drug, Adult, Antimetabolites, Antineoplastic, China, medicine.medical_specialty, Adolescent, lcsh:RC254-282, Disease-Free Survival, Young Adult, 03 medical and health sciences, Gastrectomy, Stomach Neoplasms, Esophagogastric junction adenocarcinoma, Genetics, medicine, Humans, Aged, Tegafur, Chemotherapy, business.industry, Cancer, Chemoradiotherapy, Adjuvant, medicine.disease, Adjuvant chemotherapy, Oxonic Acid, 030104 developmental biology, Preoperative chemotherapy, Gastric cancer, business, Follow-Up Studies

الوصف: The prognosis of patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma is still dismal. There are no standard treatment strategies for these patients. Multidisciplinary team (MDT) approach is a good choice for making a high-quality decision. Generally, MDT will recommend these patients to receive preoperative chemotherapy or preoperative chemoradiation based on all kinds of treatment guidelines. However, the preferred preoperative treatment is still not established. In order to solve this problem, we carry out this randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma. Eligible patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma are randomized to receive preoperative chemoradiation or preoperative chemotherapy, followed by surgery and postoperative chemotherapy. In the preoperative chemoradiation arm (Pre-CRT), patients receive two cycles of S-1 and oxaliplatin (SOX), chemoradiation, then followed by surgery and three more cycles of SOX chemotherapy. In the preoperative chemotherapy arm (Pre-CT), patients receive three cycles of SOX, following surgery three more cycles of SOX are given. The primary endpoint of this trial is to verify that preoperative chemoradiation could significantly improve the 3-year disease free survival (DFS) of patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma compared to preoperative chemotherapy. The results from this trial will provide important information about whether preoperative chemoradiation could improve survival compared to preoperative chemotherapy among patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma. ClinicalTrials.gov Identifier: NCT03013010. First posted January 6, 2017.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a373732be73174783958d40adffb407dTest
https://doi.org/10.1186/s12885-019-5728-8Test

المؤلفون: Jufang Shi, Rosa Legood, Xiang-Xian Feng, Yoon-Jung Kang, Yan Ning, Karen Canfell, Li Ma, Yong-Zhen Zhang, Megan Smith, Jie-Bin Lew, Fang-Hui Zhao, Jun-Feng Chen, Leonardo Simonella, You-Lin Qiao

المصدر: BMC Cancer, Vol 11, Iss 1, p 239 (2011)
BMC Cancer

مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Cost effectiveness, Uterine Cervical Neoplasms, Physical examination, Cervical intraepithelial neoplasia, lcsh:RC254-282, High-Throughput Screening Assays, Genetics, medicine, Humans, Mass Screening, DNA Probes, HPV, Coloring Agents, Physical Examination, Early Detection of Cancer, Mass screening, Acetic Acid, Cervical cancer, Gynecology, medicine.diagnostic_test, business.industry, Obstetrics, Papillomavirus Infections, Health Care Costs, Uterine Cervical Dysplasia, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Visual inspection, Oncology, DNA, Viral, High Grade Cervical Intraepithelial Neoplasia, Female, business, Research Article

الوصف: Background A new lower-cost rapid-throughput human papillomavirus (HPV) test (careHPV, Qiagen, Gaithersburg, USA) has been shown to have high sensitivity for the detection of high grade cervical intraepithelial neoplasia. Methods We assessed the outcomes and cost-effectiveness of careHPV screening in rural China, compared to visual inspection with acetic acid, when used alone (VIA) or in combination with Lugol's iodine (VIA/VILI). Using data on sexual behaviour, test accuracy, diagnostic practices and costs from studies performed in rural China, we estimated the cost-effectiveness ratio (CER) and associated lifetime outcomes for once-lifetime and twice-lifetime screening strategies, and for routine screening at 5-yearly, 10-yearly and IARC-recommended intervals. The optimal age range for once-lifetime screening was also assessed. Results For all strategies, the relative ordering of test technologies in reducing cervical cancer incidence and mortality was VIA (least effective); VIA/VILI; careHPV@1.0 pg/ml and careHPV@0.5 pg/ml (most effective). For once-lifetime strategies, maximum effectiveness was achieved if screening occurred between 35-50 years. Assuming a participation rate of ~70%, once-lifetime screening at age 35 years would reduce cancer mortality by 8% (for VIA) to 12% (for careHPV@0.5) over the long term, with a CER of US$557 (for VIA) to $959 (for careHPV@1.0) per life year saved (LYS) compared to no intervention; referenced to a 2008 GDP per capita in Shanxi Province of $2,975. Correspondingly, regular screening with an age-standardised participation rate of 62% (which has been shown to be achievable in this setting) would reduce cervical cancer mortality by 19-28% (for 10-yearly screening) to 43-54% (using IARC-recommended intervals), with corresponding CERs ranging from $665 (for 10-yearly VIA) to $2,269 (for IARC-recommended intervals using careHPV@1.0) per LYS. Conclusions This modelled analysis suggests that primary careHPV screening compares favourably to visual inspection screening methodologies in rural China, particularly if used as part of a regular screening program.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2bfbc51fc545c1360dba8bb7fe8cf96Test
https://doi.org/10.1186/1471-2407-11-239Test